"Immutep will apply the non-dilutive funding towards furthering its current active clinical trial programs for its lead product candidate, efti. The expected cash reach of the Company extends into early calendar year 2026."
Ann: Immutep receives Australian R&D Tax Incentive, page-2
Add IMM (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
44.5¢ |
Change
-0.015(3.26%) |
Mkt cap ! $529.0M | |||
| Open | High | Low | Value | Volume |
| 45.0¢ | 45.5¢ | 44.0¢ | $384.7K | 859.1K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 2 | 540198 | 44.5¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 45.0¢ | 115504 | 1 |
View Market Depth
| Last trade - 16.10pm 24/05/2024 (20 minute delay) ? |
|
|||||
|
Last
44.5¢ |
Change
-0.015 ( 2.20 %) |
||||
| Open | High | Low | Volume | ||
| 45.0¢ | 45.3¢ | 44.0¢ | 239211 | ||
| Last updated 15.59pm 24/05/2024 ? | |||||
| IMM (ASX) Chart |